M&A Deal Summary

Charles River Laboratories International Acquires Piedmont Research Center

On April 3, 2009, Charles River Laboratories International acquired life science company Piedmont Research Center from PPD for 46M USD

Acquisition Highlights
  • This is Charles River Laboratories International’s 4th transaction in the Life Science sector.
  • This is Charles River Laboratories International’s 13th largest (disclosed) transaction.
  • This is Charles River Laboratories International’s 3rd transaction in the United States.
  • This is Charles River Laboratories International’s 2nd transaction in North Carolina.

M&A Deal Summary
Date 2009-04-03
Target Piedmont Research Center
Sector Life Science
Buyer(s) Charles River Laboratories International
Sellers(s) PPD
Deal Type Divestiture
Deal Value 46M USD

Target

Piedmont Research Center

Morrisville, North Carolina, United States
Piedmont Research Center LLC is a provider of preclinical discovery services in oncology and other therapeutic areas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Charles River Laboratories International

Wilmington, Massachusetts, United States
Category Company
Founded 1947
Sector Life Science
Employees20,400
Revenue 4.1B USD (2023)
DESCRIPTION

Charles River Laboratories International is a provider of essential products and contract services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Charles River Laboratories International was incorporated in 1947 and is based in Wilmington, Massachusetts.

DEAL STATS #
Overall 4 of 31
Sector (Life Science) 4 of 28
Type (Divestiture) 1 of 4
State (North Carolina) 2 of 2
Country (United States) 3 of 20
Year (2009) 1 of 3
Size (of disclosed) 13 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-09-15 Molecular Therapeutics

Ann Arbor, Michigan, United States

Molecular Therapeutics, Inc. is a biotechnology company develops anti cancer agents.

Buy $13M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-07-31 Cerebricon Oy

Kuopio, Finland

Cerebricon Oy, provides pharmaceutical discovery services foused on the central nervous system (CNS) diseases category.

Buy -

Seller(S) 1

SELLER

PPD

Wilmington, North Carolina, United States
Category Company
Founded 1985
Sector Life Science
Employees26,000
Revenue 4.7B USD (2020)
DESCRIPTION

PPD is a global contract research organization providing drug discovery, development, and lifecycle management services. Its clients and partners primarily include pharmaceutical and biotechnology companies, in addition to medical device companies, academic institutions, and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPDI applies innovative technologies, therapeutic expertise, and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. PPD was founded in 1985 and is based in Wilmington, North Carolina.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Divestiture) 1 of 3
State (North Carolina) 1 of 1
Country (United States) 1 of 3
Year (2009) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-04-01 Magen BioSciences

Waltham, Massachusetts, United States

Magen BioSciences, Inc. is a provider of research and development for pharmaceutical products for the improvement of human skin.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-11-06 Excel PharmaStudies

Beijing, China

Excel PharmaStudies, Inc. is a comprehensive range of Phase II-IV clinical services, including regulatory affairs, patient recruitment, protocol design, feasibility studies, good clinical practice training and program management.

Buy -
Mergr

Product

Company

Legal